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octacosanol and policosanol 
prevent high-fat diet-induced 
obesity and metabolic disorders by 
activating brown adipose tissue and 
improving liver metabolism
Rahul sharma1, takashi Matsuzaka1,2, Mahesh K. Kaushik3, takehito sugasawa1, 
Hiroshi ohno1, Yunong Wang1, Kaori Motomura1, takuya shimura1, Yuka okajima1, 
Yuhei Mizunoe1, Yang Ma1, Zahara M. saber1, Hitoshi Iwasaki1, shigeru Yatoh1,  
Hiroaki suzuki  1, Yuichi Aita1, song-iee Han1, Yoshinori takeuchi1, Naoya Yahagi  1, 
takafumi Miyamoto1,2, Motohiro sekiya1, Yoshimi Nakagawa1,3 & Hitoshi shimano1,3,4,5
Brown adipose tissue (BAt) is an attractive therapeutic target for treating obesity and metabolic 
diseases. octacosanol is the main component of policosanol, a mixture of very long chain aliphatic 
alcohols obtained from plants. The current study aimed to investigate the effect of octacosanol and 
policosanol on high-fat diet (HFD)-induced obesity. Mice were fed on chow, or HFD, with or without 
octacosanol or policosanol treatment for four weeks. HFD-fed mice showed significantly higher 
body weight and body fat compared with chow-fed mice. However, mice fed on HFD treated with 
octacosanol or policosanol (HFDo/p) showed lower body weight gain, body fat gain, insulin resistance 
and hepatic lipid content. Lower body fat gain after octacosanol or policosanol was associated with 
increased BAt activity, reduced expression of genes involved in lipogenesis and cholesterol uptake in 
the liver, and amelioration of white adipose tissue (WAT) inflammation. Moreover, octacosanol and 
policosanol significantly increased the expression of Ffar4, a gene encoding polyunsaturated fatty acid 
receptor, which activates BAt thermogenesis. together, these results suggest that octacosanol and 
policosanol ameliorate diet-induced obesity and metabolic disorders by increasing BAt activity and 
improving hepatic lipid metabolism. thus, these lipids represent promising therapeutic targets for the 
prevention and treatment of obesity and obesity-related metabolic disorders.
Obesity, which results from a chronic imbalance between energy intake and expenditure, is a strong risk factor 
for several metabolic diseases, such as type 2 diabetes mellitus, hyperlipidaemia, atherosclerosis and nonalco-
holic fatty liver disease (NALFD). Several current anti-obesity drugs that aim to reduce food intake cause severe 
psychiatric or cardiovascular side effects1,2. Therefore, alternative safety therapeutic strategies, such as enhancing 
energy expenditure, are urgently needed to combat obesity.
White adipose tissue (WAT) is essential for the storage of excess energy as triglycerides (TGs), while brown 
adipose tissue (BAT) dissipates energy in the form of heat by uncoupling mitochondrial respiratory chain and ATP 
biosynthesis3. Active BAT has been found in adult humans, which is believed to play an essential role in metabolic 
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balance in the body4,5 and has been emerging as a promising target to treat obesity and diabetes through its energy 
expenditure pathway6,7. Some human studies have suggested that obesity might be associated with a decreased 
volume of BAT8,9, and animal studies have also shown that absence of BAT activity could aggravate obesity10–12. 
Recent studies have revealed the ability of specific WAT depots to activate thermogenesis upon exposure to cold 
and hormonal stimuli13,14. A subpopulation of cells in inguinal WAT (iWAT), known as “beige” cells, expresses 
uncoupling protein-1 (UCP-1) and carries out thermogenesis. Thus, promoting the development and function of 
brown and beige fat appears as an attractive treatment for obesity and obesity-related metabolic diseases.
Policosanol is a mixture of very-long-chain saturated fatty alcohols purified from natural sources such as rice 
bran, wheat, sugarcane and bees wax, whose main component is octacosanol (CH3(CH2)26CH2OH)15,16. Previous 
studies have demonstrated that octacosanol suppresses HFD-induced increase in peripheral adipose tissue 
weight17, lowers blood cholesterol17–21, suppresses platelet aggregation22,23, reduces inflammation24–26, increases 
athletic performance27–30, protects cells31, alleviates stress and restores stress-affected sleep32. Thus, octacosanol 
(policosanol) could be used as a drug or food supplement for treating metabolic diseases without any side effects.
A study investigating the biodistribution and metabolism of radiolabeled octacosanol in rats after oral admin-
istration has demonstrated higher octacosanol radioactivity in the liver, muscle and adipose tissue, especially 
BAT33. Moreover, previous studies have demonstrated that shortened saturated fatty acids (FAs; myristic, palmitic 
and stearic) and unsaturated FAs (oleic, palmitoleic) are formed after oral administration of policosanol to mon-
keys34. These FAs might be utilized for energy expenditure via β-oxidation35.
The β-oxidation of FAs is critical for the function of BAT and beige fat and hence thermogenesis36,37. Recent 
studies using experimental models and humans suggest that the long chain saturated FAs, mainly stearic acid 
(C18:0), regulate mitochondrial function38,39. Moreover, the ELOVL family member 6 (Elovl6), a microsomal 
enzyme responsible for converting C16 FAs into C18 species, has been suggested to regulate BAT thermogenic 
capacity40.
Considering that the longer FAs could be preferred substrates for thermogenesis and the abovementioned 
effects of octacosanol or policosanol on lipid metabolism, their role in the prevention or treatment of obesity and 
in the thermogenic function of brown and beige adipocytes has not yet been established. In the present study, we 
investigated anti-obesity and thermogenic function of octacosanol and policosanol in mice.
Results
octacosanol and policosanol prevent HFD-induced obesity. To investigate the effect of octacosanol 
and policosanol on the development of obesity, male C57BL/6 mice were fed on normal chow, HFD, or HFDo/p 
for four weeks. The body weight (BW) of HFD-fed mice was significantly higher than that of chow-fed mice 
(Fig. 1a). Treatment with octacosanol or policosanol suppressed the HFD-induced BW gain (Fig. 1a,b). The fat 
mass gain was significantly less in mice fed on HFDo/p compared with HFD-fed mice (Fig. 1c). The lean body 
mass tended to reduce in mice fed on HFDo/p compared with chow- or HFD-fed mice (Fig. 1d). Total body fat 
percentage was also significantly lower in mice fed on HFDo/p (Fig. 1e). The weight of epididymal WAT (eWAT) 
(Fig. 1f), iWAT (Fig. 1g) and BAT (Fig. 1h) was significantly reduced in HFD-fed mice supplemented with octa-
cosanol and policosanol.
octacosanol or policosanol treatment of HFD reduces plasma insulin levels. Figure 2 compares 
plasma metabolic parameters in four dietary groups; chow-fed, HFD-fed, HFD treated with octacosanol or pol-
icosanol on the 4 h fasted condition. Plasma glucose levels did not show a significant increase in the HFD group 
compared with the chow group (Fig. 2a). The treatment of HFDo/p did not change plasma glucose levels. Plasma 
insulin levels were markedly increased in the HFD group (Fig. 2b), demonstrating that HFD causes insulin resist-
ance. Conversely, insulin resistance induced by the HFD was efficiently attenuated by the HFDo/p, as reflected in 
significantly decreased plasma insulin levels than in HFD-fed mice. Previous studies have shown that octacosanol 
supplementation reduces serum lipid concentrations in mice17,18. However, HFD-fed mice treated with octacos-
anol or policosanol showed no significant reduction in the plasma levels of TG, total cholesterol (TC), and free 
fatty acids (FFA) compared with those of HFD-fed mice (Fig. 2c–e).
octacosanol and policosanol activate BAt in HFD-fed mice. Previous studies have shown that orally 
administered octacosanol was distributed to adipose tissue, especially BAT, and is partly oxidized and degraded 
to FAs through β-oxidation33–35. Thus, we investigated the effects of octacosanol and policosanol on BAT (Fig. 3). 
Histological analysis revealed that the BAT of HFD-fed mice showed markedly enlarged adipocytes compared 
with that of chow-fed mice (Fig. 3a). However, the HFDo/p prevented HFD-induced enlargement of adipo-
cytes in BAT, indicating reduced lipid accumulation within the tissue probably because they were used more 
as a metabolic fuel. Western blot analysis showed that protein level of UCP-1 was significantly increased by the 
HFDo/p (Fig. 3b,c). Moreover, UCP-1 immunohistochemistry further revealed higher levels of UCP-1 in the 
BAT of HFDo/p-fed mice compared with that of chow- or HFD-fed mice (Supplementary Fig. S1). The expres-
sion of thermogenic genes, including Ucp1, peroxisome proliferative activated receptor, gamma, co-activator 1α 
(Ppargc1a), β3-adrenergic receptor (Adrb3), FFA receptor 4 (Ffar4), and Elovl3, was significantly increased in 
BAT of mice fed on HFDo/p (Fig. 3d). Furthermore, mice fed on HFDo/p exhibited a higher core body temper-
ature than chow- or HFD-fed mice (Fig. 3e). These results suggest that octacosanol and policosanol activate BAT 
activation through the upregulation of thermogenic gene expression.
octacosanol and policosanol upregulate genes involved in adaptive thermogenesis in iWAt of 
HFD fed mice. Beiging of iWAT has been highlighted as a new possible therapeutic target for obesity, diabetes 
and lipid metabolic disorders because beiging of iWAT is known to increase energy expenditure and reduce adi-
posity3. Since our results suggest that octacosanol and policosanol activate non-shivering thermogenesis in BAT 
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and reduce body fat, we assessed the effect of octacosanol and policosanol on iWAT. Histological analysis showed 
large adipocytes in iWAT in HFD-fed mice; however, mice fed on HFDo/p showed significantly smaller adipocytes 
in iWAT (Fig. 4a,b). Next, we examined whether the diminished adipocyte size in mice fed on HFDo/p could be 
the result of increased beiging of iWAT. We found that the HFDo/p increased the expression of genes involved in 
adaptive thermogenesis, such as Ppargc1a, PR domain containing 16 (Prdm16), Ppara, cell death-inducing DNA 
fragmentation factor, alpha subunit-like effector A (Cidea), and Ffar4, as well as citrate synthase (Cs), a crucial 
component of the tricarboxylic (TCA) cycle of mitochondria (Fig. 4c). However, we unexpectedly found that the 
mRNA levels of Ucp1 and its transcriptional regulator PPAR gamma (Pparg) and the protein level of UCP-1 was 
not increased in the iWAT of HFDo/p-fed mice (Fig. 4c–e). These data suggest that octacosanol and policosanol 
activate energy combustion but do not fully promote the iWAT beiging in HFD-fed mice.
octacosanol and policosanol reduce adipocyte size and lower inflammation in epididymal 
WAt (eWAt) in HFD-fed mice. We also examined the effect of octacosanol and policosanol on eWAT. 
Histological analysis showed reduced adipocyte size in eWAT of mice fed on HFD treated with octacosanol or 
Figure 1. Effect of octacosanol and policosanol on body weight, body composition and fat accumulation in 
mice fed on chow, high fat diet (HFD) and HFD treated with octacosanol or policosanol. (a,b) Body weight (a) 
and body weight gain (b) of mice fed on chow, HFD and HFD treated with octacosanol or policosanol (60 mg/
kg/day) for four weeks (n = 7–8). (c–e) Changes in fat mass (c), lean mass (d) and percent fat (e) measured by 
dual-energy X-ray absorptiometry (DEXA) analysis (n = 5). (f–h) Weight of epididymal white adipose tissue 
(eWAT) (f), inguinal WAT (iWAT) (g), brown adipose tissue (BAT) (h) of mice fed on chow, HFD and HFD 
treated with octacosanol or policosanol for four weeks (n = 7–8). Values represent mean ± standard error of 
mean (SEM). *P < 0.05, **P < 0.01, ***P < 0.001 by using one-way ANOVA followed by scheffe post hoc test.
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policosanol (Fig. 5a,b). Since octacosanol also possesses anti-inflammatory activity24–26, we examined the effects 
of octacosanol and policosanol on HFD-induced adipose tissue inflammation. In line with the reduced eWAT 
weight (Fig. 1f), immunohistochemical staining of eWAT sections for CD68, a marker of infiltrated macrophage, 
revealed that crown-like structures in mice fed on HFDo/p were markedly reduced relative to mice fed on HFD 
(Fig. 5c). Moreover, the expression of genes associated with inflammation including F4/80, Cd68 antigen (Cd68), 
tumor necrosis factor α (Tnfa) and interleukin 1 β (Il1b) was markedly upregulated in the eWAT of mice fed on 
HFD (Fig. 5d). The induction of these genes was suppressed in mice fed on HFDo/p. These results suggest that, 
besides preventing fat accumulation in WAT, octacosanol and policosanol also prevent HFD-induced adipose 
tissue inflammation.
octacosanol and policosanol attenuate fatty liver in HFD-fed mice. The liver regulates energy 
metabolism in the body through the dynamic control of glucose and lipid metabolism. Therefore, we investi-
gated the effect of octacosanol and policosanol on the liver. The weight of liver in HFD-fed mice was lower than 
in chow-fed mice (Fig. 6a); however, HFD markedly increased hepatic levels of TG and TC (Fig. 6b). While the 
liver weights were similar between HFD-fed mice and HFDo/p-fed mice (Fig. 6a), hepatic levels of TG and TC 
were significantly lower in the HFDo/p group compared with the HFD group (Fig. 6b,c). These results suggest 
that octacosanol or policosanol supplementation attenuates the increase in hepatic TG and TC levels caused by 
HFD. The expression of genes involved in lipogenesis and β-oxidation was analysed by quantitative real-time PCR 
(qRT-PCR) (Fig. 6d). Expression levels of sterol regulatory element-binding protein-1c (Srebf1c) and its down-
stream genes involved in lipogenesis such as FA synthase (Fasn), Elovl6, stearoyl-CoA desaturase-1 (Scd1) and 
glycerol-3-phosphate acyltransferase, mitochondrial (Gpam) were significantly increased in HFD-fed mice com-
pared with chow-fed mice. Expression levels of Elovl6 and Gpam in mice fed on HFDo/p, and of Srebf1c and Fasn 
in mice fed on HFD treated with policosanol were significantly lower than in HFD-fed mice. Expression levels 
of PPAR alpha (Ppara) and its target genes involved in β-oxidation, including carnitine palmitoyltransferase 1a 
(Cpt1a) and acyl-Coenzyme A dehydrogenase, medium chain (Acadm), were significantly increased in HFD-fed 
mice compared with chow-fed mice. HFDo/p significantly reduced Ppara expression; it also reduced the expres-
sion levels of Cpt1a and Acadm, although the reduction was non-significant. We also examined the expression 
levels of genes involved in cholesterol biosynthesis and uptake. Results showed that the treatment of octacosa-
nol or policosanol significantly suppressed HFD-induced increase in the expression of low density lipoprotein 
receptor (Ldlr) (Fig. 6e). Moreover, the treatment of HFDo/p tended to reduce the expression levels of Srebf2 and 
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (Hmgcs1), and octacosanol treatment significantly reduced 
3-hydroxy-3-methylglutaryl-Coenzyme A reductase (Hmgcr) expression. The expression level of lipoprotein 
lipase (Lpl), the rate-limiting enzyme to catalyze the hydrolysis of TG in circulation41, is similar in all groups. 
Collectively, these results suggest that octacosanol and policosanol ameliorate the development of HFD-induced 
fatty liver by suppressing the biosynthesis of FAs and TGs and uptake of cholesterol by the liver.
Figure 2. Effect of octacosanol and policosanol on plasma metabolic parameters of mice fed on chow, HFD and 
HFD treated with octacosanol or policosanol. (a–e) Concentrations of blood glucose (a), plasma insulin (b), 
plasma triglycerides (TGs) (c), plasma total cholesterol (TC) (d) and plasma free fatty acids (FFA) (e) of mice 
fed on chow, HFD and HFD treated with octacosanol or policosanol for four weeks (n = 5). Values represent 
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by using one-way ANOVA followed by scheffe post hoc test.
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octacosanol activates BAt and iWAt in normal chow-fed mice. To examine whether HFD is nec-
essary for the effect of octacosanol and policosanol on BAT and iWAT, we investigated the effect of octacosanol 
on chow-fed mice. Mice fed on standard chow supplemented with octacosanol for seven days showed signif-
icantly higher mRNA levels of genes involved in BAT function, including Ucp1, Adrb3, Ffar4, and fibroblast 
growth factor 21 (Fgf21) (Fig. 7a). Similarly, higher mRNA levels of Ucp1 and other marker genes for adaptive 
thermogenesis such as Ppara, Ffar4, and Fgf21 were observed in the iWAT of mice fed on standard chow treated 
with octacosanol. Moreover, expression levels of Elovl6 and Elovl3, genes encoding FA elongases involved in the 
biosynthesis of long chain and very long chain saturated FAs, were significantly increased in BAT and tended to 
increase in iWAT, respectively, following octacosanol treatment. These data suggest that octacosanol activates 
BAT and iWAT not only in mice fed on HFD (as shown above) but also in mice fed on chow.
Figure 3. Effect of octacosanol and policosanol on brown adipose tissue (BAT) of mice fed on chow, HFD 
and HFD treated with octacosanol or policosanol. (a) Representative hematoxylin and eosin (H&E)-stained 
sections of BAT harvested from mice fed on chow, HFD and HFD treated with octacosanol or policosanol for 
four weeks. (b) Western blotting of UCP-1 and GAPDH in BAT (n = 5). GAPDH was used as a loading control. 
(c) Protein expression of UCP-1 determined by densitometry analysis (n = 5). (d) Quantitative real-time PCR 
(qRT-PCR) analysis of genes involved in thermogenesis of BAT in mice fed on chow, HFD and HFD treated 
with octacosanol or policosanol for four weeks (n = 5–8). (e) Rectal temperature of mice fed on chow, HFD and 
HFD treated with octacosanol or policosanol for four weeks (n = 5). Values represent mean ± SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001 by using one-way ANOVA followed by scheffe post hoc test.
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Discussion
This study aimed to determine whether purified octacosanol and policosanol have beneficial effects on 
HFD-induced obesity in mice. We showed that both octacosanol and policosanol significantly ameliorated 
HFD-induced body fat gain and fatty liver. Furthermore, octacosanol and policosanol activated signalling path-
ways that regulate thermogenesis and enhance energy expenditure in BAT.
Octacosanol or policosanol treatment completely suppressed HFD-induced BW gain. This is presumably 
due to not only the significant reduction of adipose tissue mass but also the slight reduction of lean mass. The 
organ(s) that contributes to the reduction of lean mass by the treatment of octacosanol or policosanol is currently 
unknown. Previous study investigating the biodistribution of radiolabeled octacosanol in rats after oral adminis-
tration has demonstrated moderate octacosanol radioactivity in digestive tracts, spleen, kidney, heart, and lung33. 
Further study is required to understand the effect of octacosanol and policosanol in various organs.
Several factors are involved in energy expenditure and thermogenesis in BAT and beige fat3,13,14. Policosanol 
is a fatty alcohol, which is converted to saturated and monounsaturated FAs by fatty aldehyde dehydrogenase 
Figure 4. Effect of octacosanol and policosanol on inguinal white adipose tissue (iWAT) of mice fed on chow, 
HFD and HFD treated with octacosanol or policosanol. (a) Representative H&E-stained sections of iWAT 
harvested from mice fed on chow, HFD and HFD treated with octacosanol or policosanol for four weeks. 
Scale bar = 30 μm. (b) Average adipocyte size in iWAT of mice fed on chow, HFD and HFD treated with 
octacosanol or policosanol for four weeks (n = 5). (c) qRT-PCR analysis of beige fat markers in iWAT harvested 
from mice fed on chow, HFD and HFD treated with octacosanol or policosanol for four weeks (n = 5–8). (d) 
Western blotting of UCP-1 and GAPDH in iWAT (n = 4–5). GAPDH was used as a loading control. (e) Protein 
expression of UCP-1 determined by densitometry analysis (n = 4–5). Values represent mean ± SEM *P < 0.05, 
**P < 0.01, ***P < 0.001 by using one-way ANOVA followed by scheffe post hoc test.
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(FALDH, alternatively known as Aldh3a2)42,43. Fatty aldehydes are also implicated in thyroid function44, cell 
proliferation45, adipogenesis and signalling pathways involving PPARγ46. In this study, we also observed higher 
expression of Aldh3a2 in iWAT of HFDo/p mice and in BAT and iWAT of chow-fed mice treated with octacos-
anol (Supplementary Fig. S2), suggesting the conversion of octacosanol and policosanol into FAs in BAT and 
iWAT. Previous studies have suggested that orally administrated octacosanol and policosanol may be oxidised 
and degraded into shortened saturated and monounsaturated FAs via β-oxidation in vivo33–35. Thus, another 
possibility is that octacosanol and policosanol may be degraded to FAs via β-oxidation in liver, which were then 
transported to BAT and WAT to be utilized for thermogenesis. Additionally, long chain and very long chain 
saturated and monounsaturated FAs synthesized via Elovl6 and Elovl3 regulate mitochondrial function and ther-
mogenic capacity in BAT and iWAT38–40,47,48. Our findings suggest the possibility that shortened saturated and 
unsaturated FAs metabolized from octacosanol and policosanol perform cellular functions important for thermo-
genesis and energy expenditure in BAT and WAT. Further studies are needed to confirm this possibility.
Figure 5. Effect of octacosanol and policosanol on epididymal WAT (eWAT) of mice fed on chow, HFD and 
HFD treated with octacosanol or policosanol. (a) Representative H&E-stained sections of eWAT harvested from 
mice fed on chow, HFD and HFD treated with octacosanol or policosanol for four weeks. Scale bar = 30 μm. (b) 
Average adipocyte size in eWAT of mice fed on chow, HFD and HFD treated with octacosanol or policosanol 
for four weeks (n = 5). (c) Representative immunohistochemical staining for CD68 in eWAT sections of mice 
fed on chow, HFD and HFD treated with octacosanol or policosanol for four weeks. (d) qRT-PCR analysis 
of genes involved in the inflammation of iWAT harvested from mice fed on chow, HFD and HFD treated 
with octacosanol or policosanol for four weeks (n = 5). Values represent mean ± SEM. *P < 0.05, **P < 0.01, 
***P < 0.001 by using one-way ANOVA followed by scheffe post hoc test.
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Recent studies have shown that FFAR4 (GPR120), a receptor for polyunsaturated FAs (PUFAs), plays a piv-
otal role in the thermogenic activity of BAT and browning of WAT49–51. Activation of FFAR4 by n-3 PUFA or a 
selective agonist increases FA oxidation and reduces BW and body fat by inducing BAT activity and promoting 
the browning of WAT. In this study, we showed that the treatment of HFDo/p induced Ffar4 expression in BAT 
and iWAT of mice and decreased lipid content in BAT and WAT. This suggests that brown/beige fat activation by 
octacosanol or policosanol could be mediated at least partially through upregulating Ffar4 expression in BAT and 
iWAT of HFD-induced mice.
Besides improving metabolism, octacosanol also possesses anti-inflammatory properties24–26. In obesity, a 
paracrine loop between adipocytes and macrophages augments chronic inflammation of adipose tissue, thereby 
inducing systemic insulin resistance and ectopic lipid accumulation52. Since adipose tissue in obese individ-
uals is characterized by adipocyte hypertrophy and chronic inflammation, we also investigated the effects of 
octacosanol and policosanol on the inflammatory state of WAT. Treatment of HFDo/p lowered the expression 
levels of pro-inflammatory genes including F4/80, Cd68, Tnfa and Il1b in eWAT. Previously, a high concen-
tration of octacosanol has been shown to inhibit the mitogen-activated protein kinase/nuclear factor-kappa 
B/ activator protein-1 signalling pathway involved in the regulation of inflammation in macrophages26. This 
anti-inflammatory effect of octacosanol and policosanol might contribute to the improvement of systemic insulin 
resistance induced by HFD. Moreover, octacosanol and policosanol-induced Ffar4 expression might contribute 
toward the anti-inflammatory effect of octacosanol and policosanol because FFAR4 activation by n-3 PUFA trig-
gers a broad spectrum of anti-inflammatory effects in macrophages53,54.
Figure 6. Effect of octacosanol and policosanol on the liver ofmice fed on chow, HFD and HFD treated with 
octacosanol or policosanol. (a–c) Liver weight (a) and hepatic levels of TG (b) and TC (c) in mice fed on chow, 
HFD and HFD treated with octacosanol or policosanol for four weeks (n = 5–8). (d,e) qRT-PCR analysis of 
genes involved in fatty acid (FA) metabolism (d) and cholesterol biosynthesis (e) in livers harvested from mice 
fed on chow, HFD and HFD treated with octacosanol or policosanol for four weeks (n = 5). Values represent 
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by using one-way ANOVA followed by scheffe post hoc test.
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Several studies reported potential serum lipid-lowering effect of octacosanol in rabbits18, rats fed an HFD17, 
and hyperlipidemic patients55,56. In our experiment using HFD-fed C57BL/6J mice, we were unable to reproduce 
this benefit. This discrepancy may be due to different dose and duration of administration, animal species, and the 
degree of hyperlipidemia. In agreement with our result, policosanol treatment failed to lower serum cholesterol in 
subjects with normal or moderately elevated cholesterol concentrations19.
Previous studies have demonstrated that octacosanol and policosanol inhibits cholesterol synthesis in ani-
mals57 and cultured cells20,58. Similar results were obtained in the present study. Octacosanol and policosanol sig-
nificantly decreased hepatic TC levels accompanied by downregulation of Ldlr expression in the liver of HFD-fed 
mice, suggesting that these lipids suppressed cholesterol uptake in the liver. Also, the downregulation of lipogenic 
genes by the treatment of octacosanol and policosanol could contribute to reduce hepatic TG accumulation in the 
liver. We showed that octacosanol and policosanol reduced hepatic TG accumulation in HFD-fed mice by 32% 
and 18%, respectively. These reductions are equivalent to the estimated the contribution of de novo lipid synthesis 
to hepatic TG content (close to 30% came from de novo lipogenesis) in NAFLD patients59. It remains unclear if 
dietary octacosanol and policosanol can affect lipid absorption from the intestine, but one study reported that 
lipid absorption was not affected by octacosanol in HFD-fed rat17.
In conclusion, we show that octacosanol and policosanol exert beneficial metabolic effects by activating 
thermogenic changes in HFD-induced obesity in mice. Although precise molecular mechanisms underlying 
the involvement of octacosanol and policosanol in the thermogenic activity of BAT and iWAT remains to be 
determined, our data shown that octacosanol and policosanol are potent dietary anti-obesity molecules, which 
increase the thermogenic activity of BAT, thereby increasing energy expenditure and reducing body fat.
Methods
Animals and growth conditions. All animal husbandry and animal experiments complied with reg-
ulations of the University of Tsukuba for animal experiments and were approved by the Animal Experiment 
Committee of the University of Tsukuba. Seven-week-old C57BL/6 mice were obtained from CLEA Japan (Tokyo, 
Japan). Mice were housed in colony cages under a 12 h light/12 h dark cycle, with unlimited access to food and 
water. At 10 weeks of age, mice were randomly divided into the following four groups: chow group (fed on 
standard chow with vehicle treatment), HFD group (fed with vehicle treatment), the HFD + octacosanol group 
(60 mg/kg/day; Sigma-Aldrich, Tokyo, Japan), and HFD + policosanol group (60 mg/kg/day; NOF, Tokyo, Japan). 
Octacosanol and policosanol were dissolved in 10 mg/ml Acacia-gum water. Octacosanol, policosanol, or the 
same volume of vehicle was administered via oral gavage once a day for four weeks. At the end of four weeks, all 
mice were sacrificed in the early light phase in a non-fasting state. HFD was obtained from Oriental Yeast (Tokyo, 
Japan) and the composition of HFD is shown in Supplementary Table S1. The policosanol extracted from rice 
Figure 7. Effect of octacosanol on gene expression in BAT and iWAT harvested from mice fed a chow diet. 
(a,b) qRT-PCR analysis of genes involved in thermogenesis and energy expenditure of BAT (a) and iWAT (b) in 
mice fed on chow, with or without octacosanol treatment, for seven days (n = 5). Values represent mean ± SEM. 
*P < 0.05, **P < 0.01, ***P < 0.001 vs. control (vehicle-treated) mice by using student-t-test.
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bran oil was obtained from NOF (Tokyo, Japan). The composition of aliphatic alcohols in policosanol is C22; 1%, 
C24; 9%, C26; 9%, C28; 18%, C30; 21%, C32; 9%, C34; 16%, C36; 14%, and others; 3%.
Dual-energy X-ray absorptiometry (DeXA) analysis. PIXImus2 DEXA (GE Medical Systems Lunar, 
Madison, WI, USA) was used to measure the weight and percent lean body tissue and fat mass.
Metabolic measurements. Glucose, insulin, TG, TC and FFA levels in plasma and TG and TC levels in 
the liver were determined as described previously60. Blood samples were taken during the light phase after food 
deprivation for four hours.
Body temperature measurement. Core body temperature was measured between 5:00 PM and 6:00 
PM using a rectal probe attached to a digital thermometer (RET-3 rectal probe, BRC BDT-100 thermometer; 
Physitemp, Clifton, NJ).
Histological analysis. Interscapular BAT (iBAT), iWAT, and eWAT were removed, fixed in 10% buff-
ered formalin, embedded in paraffin, cut into 4 µm thick sections and used for hematoxylin and eosin (H&E) 
staining and immunohistochemistry as described previously61. Immunohistochemical staining for UCP-1 
(1:400, ab10983; Abcam, Cambridge, UK) and CD68 (1:400, MCA1957GA; Bio-Rad, Hercules, USA) primary 
antibodies and detection with secondary antibodies (anti-rabbit IgG, Alexa Fluor 555 conjugate, 1:500, #4413; 
Cell Signaling Technology Japan, Tokyo, Japan or goat anti-rat IgG, Alexafluor 488 conjugate, 1:500, ab150157; 
Abcam, Cambridge, UK) was performed as previously described62. All images were acquired using a BZ-X710 
microscope (Keyence, Osaka, Japan) and data were analysed using a BZ-H3 Analyzer (Keyence, Osaka, Japan). 
Adipocyte cell size was measured using ImageJ software (National Institutes of Health, Bethesda, MD) and at least 
300 cells were counted in each sample.
Western blotting. Western blotting was performed as previously described60. Aliquots of whole cell lysate 
(30 μg) proteins extracted from BAT or iWAT were loaded onto 10% SDS-PAGE gels and transferred to PDVF 
membranes (Millipore, Darmstadt, Germany). Membranes were probed with anti-UCP-1 (1:1000, ab10983; 
Abcam, Cambridge, UK) and anti-GAPDH (1:5000, sc-32233; Santa Cruz Biotechnology, Dallas, Texas, USA) 
followed by horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit IgG (Cell Signaling Technology 
Japan, Tokyo, Japan). Immune complexes were visualized using enhanced chemiluminescence (GE Healthcare 
Japan, Tokyo, Japan).
RNA extraction and quantitative real-time pCR (qRt-pCR). Total RNA was extracted from BAT, 
iWAT, eWAT and liver and used for cDNA synthesis and qRT-PCR as described previously60–63. Primer sequences 
for Adrb3, Aldh3a2, Cs, Elovl3, Fgf21 and Ffar4 are listed in Supplementary Table S2. The mRNA levels of these 
genes were normalized relative to cyclophilin mRNA and expressed relative to the appropriate experimental 
control using the ΔΔCT method.
statistical analysis. All data are expressed as the mean ± SEM. Data were compared using Student’s t-test 
(between two groups) or analysis of variance (ANOVA; more than two groups) followed with scheffe post hoc 
analysis and were considered statistically significant if p < 0.05.
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